当前位置:首页 >财报库 > 报告详情

再鼎医药Zai Lab Limited(ZLAB)2025年第三季度财务业绩和近期公司进展「NASDAQ」(英文版)(22页).pdf

上传人: 1****1 编号:970107 2025-11-18 22页 1.21MB

下载:

1、November 2025Third Quarter 2025 Financial Results and Recent Corporate Updates Forward-Looking StatementsThis presentation contains forward-looking statements,including statements relating to our strategy and plans;potential of and expectations for our business,commercial products,and pipeline progr

2、ams;our goals,objectives,and priorities and our expectations under our growth strategy(including our expectations regarding our commercial products and launches,clinical stage products,revenue growth/CAGR,profitability and timeline to profitability,operating margins,and cash flow);the peak sales pot

3、ential of our programs;capital allocation and investment strategy;clinical development programs and related clinical trials;expected timing and results of clinical trial data,data readouts,and presentations;risks and uncertainties associated with drug development,commercialization and outreach;regul

4、atory discussions,submissions,filings,and approvals and the timing and scope thereof;the potential benefits,safety,and efficacy of our products and product candidates and those of our collaboration partners;the anticipated benefits and potential of investments,collaborations,and business development

5、 activities;the potential market opportunities of,and estimated addressable markets for,our drug candidates;our future financial and operating results;and financial guidance.All statements,other than statements of historical fact,included in this presentation are forward-looking statements,and can b

6、e identified by words such as“aim,”“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“possible,”“potential,”“target,”“will,”“would,”and other similar expressions.Such statements constitute forward-looking statements within the meaning of U.S.federa

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是全文关键点的概括: 1. **公司战略与展望**:Zai Lab致力于成为连接中国生物科技生态和全球市场的桥梁,预计在未来1-2年内显著提高运营杠杆。 2. **全球管线进展**:Zoci(DLL3 ADC)在SCLC治疗中取得积极进展,预计2027/2028年获得全球批准;IL-13/IL31R和LRRC15 ADC正在推进临床试验。 3. **中国市场**:VYVGART在重症肌无力和多发性硬化症治疗中表现强劲,预计2026-2027年有多款重磅产品上市。 4. **财务状况**:第三季度总收入增长14%,研发和一般及行政费用下降,现金储备8.17亿美元,支持业务发展和发现工作。 5. **关键数据**:Zoci在SCLC治疗中ORR为68%,VYVGART治疗的重症患者超过21,000例。
2027/28年全球首批准备?" 中国重症肌无力新篇章?" 肺癌新希望?"
客服
商务合作
小程序
服务号
折叠